Lobbying Filing Details

Total Spending

$960,000

Activities

4

Lobbyists

3

Gov't Entities

8

Filing Information
Filing UUID:
81ee4ed4-1076-4bb7-b2cd-05e974957987
Type:
Q1 - 1st Quarter - Report
Period:
2024 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
April 22, 2024 at 8:46 PM
Income:
$0
Expenses:
$960,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Christine Bloomquist
Registrant
ASTELLAS PHARMA US, INC.

Pharmaceuticals

Northbrook, Illinois
Client
ASTELLAS PHARMA US, INC.
Illinois, United States of America
Lobbying Activities (4)
Activity 1
Copyright/Patent/Trademark

Issues related to Bayh-Dole Act (Pub.L. 96-517).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • JONATHAN OEHMEN
  • AKSHAI DATTA
  • STEPHEN RUBRIGHT
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • JONATHAN OEHMEN
  • AKSHAI DATTA
  • STEPHEN RUBRIGHT
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Insurance

Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • JONATHAN OEHMEN
  • AKSHAI DATTA
  • STEPHEN RUBRIGHT
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Medicare/Medicaid

Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • JONATHAN OEHMEN
  • AKSHAI DATTA
  • STEPHEN RUBRIGHT
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.